Browse All

Current Filters

CLEAR FILTER x

TITLE

Effect of Zilucoplan on Myasthenia Gravis–Specific Outcome Subdomain Scores in RAISE: A Phase 3 Study

Author:Weiss, Michael D.   Farmakidis, Constantine   Freimer, Miriam   Genge, Angela   Hewamadduma, Channa   Hussain, Yessar   Leite, M. Isabel   Maniaol, Angelina   Utsugisawa, Kimiaki   Vu, Tuan   Boroojerdi, Babak   Grimson, Fiona   Savic, Natasa   Howard Jr., James F.   

Session Name:S34: Updates on Myasthenia Gravis  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:S34.004  

Author Institution:Department of Neurology, University of Washington Medical Center, Seattle, WA, USA, Seattle, WA  Department of Neurology, Neuromuscular Division, University of Kansas Medical Center, Kansas City, KS, USA, Kansas City, KS  Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA, Columbus, OH  Clinical Research Unit, The Montreal Neurological Institute, Montreal, QC, Canada, Montreal, QC, Canada  Academic Neuroscience Unit, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK  Sheffield Institute for Translational Neurosciences (SITraN), University of Sheffield, Sheffield, UK , Sheffield, United Kingdom  Department of Neurology, Dell Medical School, The University of Texas at Austin, Austin, TX, USA, Austin, TX  Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK, Oxford, United Kingdom  Department of Neurology, Oslo University Hospital, Oslo, Norway, Oslo, Norway  Department of Neurology, Hanamaki General Hospital, Hanamaki, Japan, Hanamaki, Japan  Department of Neurology, University of South Florida Morsani College of Medicine, Tampa, FL, USA, Tampa, FL  UCB, Monheim, Germany, Monheim, Germany  UCB, Slough, UK, Slough, United Kingdom  UCB, Bulle, Switzerland, Bulle, Switzerland  Department of Neurology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, Chapel Hill, NC  

Switching to Subcutaneous Zilucoplan from Intravenous Complement Component 5 Inhibitors in Myasthenia Gravis: Patient Preference and Satisfaction from a Phase 3b Study

Author:Freimer, Miriam   Desai, Urvi   Govindarajan, Raghav   Kang, Min K.   Khan, Shaida   Khatri, Bhupendra   Levine, Todd   Macwan, Samir   Shieh, Perry B.   Weiss, Michael D.   Bloemers, Jos   Boroojerdi, Babak   Delicha, Eumorphia Maria   Lavrov, Andreea   Singh, Puneet   Howard Jr., Ja   

Session Name:P1: Neuromuscular and Clinical Neurophysiology (EMG): Myasthenia Gravis 1  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:P1.009  

Author Institution:The Ohio State University Wexner Medical Center, Columbus, OH, USA, Columbus, OH  Atrium Health, Wake Forest University, Charlotte, NC, USA, Charlotte, NC  HSHS St. Elizabeth’s Hospital, O’Fallon, IL, USA, O'Fallon, IL  University of California, San Francisco, San Francisco, CA, USA, San Francisco, CA  UT Southwestern Medical Center, Dallas, TX, USA, Dallas, TX  The Regional MS Center and Center for Neurological Disorders, Milwaukee, WI, USA, Milwaukee, WI  HonorHealth Neurology, Bob Bové Neuroscience Institute, Scottsdale, AZ, USA, Scottsdale, AZ  Eisenhower Health, Rancho Mirage, CA, USA, Rancho Mirage, CA  University of California, Los Angeles, Los Angeles, CA, USA, Los Angeles, CA  University of Washington Medical Center, Seattle, WA, USA, Seattle, WA  UCB, Brussels, Belgium, Brussels, Belgium  UCB, Monheim, Germany, Monheim, Germany  UCB, Braine-l’Alleud, Belgium, Braine-l’Alleud, Belgium  UCB, Slough, UK, Slough , United Kingdom  The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, Chapel Hill, NC  

Self-administration of Rozanolixizumab in Patients with Generalized Myasthenia Gravis: The MG0020 Study

Author:Bril, Vera   Antozzi, Carlo   Berkowicz, Tomasz   Druzdz, Artur   Gandhi Mehta, Rachana K.   Mahuwala, Zabeen K.   Zschüntzsch, Jana   Boehnlein, Marion   Lavrov, Andreea   Morris, Mark   Singh, Puneet   Leite, M. Isabel   

Session Name:P1: Neuromuscular and Clinical Neurophysiology (EMG): Myasthenia Gravis 1  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:P1.018  

Author Institution:University Health Network, Toronto, ON, Canada, Toronto, ON, Canada  Neuroimmunology and Muscle Pathology Unit, Multiple Sclerosis Center, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Neurologico Carlo Besta, Milan, Italy, Milan, Italy  Miejskie Centrum Medyczne JONSCHER im. dr Karola Jonschera w Lodzi, Lódz, Poland, Lódz, Poland  Department of Neurology, Municipal Hospital, Poznan, Poland, Poznan, Poland  Department of Neurology, Wake Forest University School of Medicine, Winston-Salem, NC, USA, Winston-Salem, NC  Department of Neuromuscular Medicine, Epilepsy and Clinical Neurophysiology, University of Kentucky, Lexington, KY, USA, Lexington, KY  Department of Neurology, University Medical Center Göttingen, Göttingen, Germany, Göttingen, Germany  UCB, Monheim, Germany, Monheim, Germany  UCB, Slough, UK, Slough, United Kingdom  Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK , Oxford, United Kingdom